Drug may be breakthrough to treat lung cancer
By Hudson Institute communications. Reviewed by Dr Mohamed Saad
The development of a drug to treat the most common type of lung cancer is a step closer, thanks to research from PhD student, Mohamed Saad, and laboratory head, Professor Brendan Jenkins, at Hudson Institute. The breakthrough to potential treatment for lung adenocarcinoma has been the discovery of how to inhibit the cancer-causing gene, KRAS.
Scientists already recognised KRAS is a common cause of lung adenocarcinoma, because when this gene mutates unexpectedly – in about one third of lung cancer cases – it can lead to the development and spread of cancer cells. What they didn’t know was that an enzyme, ADAM17, could directly impact on KRAS and its ability to control proliferation of lung cancer cells. The discovery of this relationship has opened a pathway to an effective treatment in KRAS mutant lung cancers.
Now, research, published in EMBO Molecular Medicine, has shown how a drug targeting ADAM17, and thus indirectly inhibiting the role of KRAS, could provide effective treatment for lung cancer patients. The drug supresses the mutant KRAS gene’s ability to spread cancer cells in the lung. The drug is being developed at the Weizmann Institute of Science in Israel, with support from Kiel University in Germany, while its effectiveness is being tested at Hudson Institute.
Next steps
The Hudson Institute-led team will now explore the development of this drug, in collaboration with colleagues in Israel and Germany, as a new therapy in human lung adenocarcinoma patients. They hope to provide patients with more treatment options.
Lung adenocarcinoma facts
- Each year, 1.8 million people worldwide are diagnosed with lung cancer.
- From that figure, about 85 per cent are classified as having non-small lung cancer.
- Of this 85 per cent, about 40 per cent will be classified as having lung adenocarcinoma.
- This statistic makes it the most common form of lung cancer.
Collaborators | Garvan Institute, Monash University, RMIT University, Kiel University (Germany), Nagoya University (Japan), Weizmann Institute of Science (Israel)
This research was supported by | National Health and Medical Research Council (NHMRC), United States Department of Defence, Victorian Government (Department of Health and Human Services)
Journal | EMBO Molecular Medicine
Title | ADAM17 selectively activates the IL‐6 trans‐signaling/ERK MAPK axis in KRAS‐addicted lung cancer
In this article
About Hudson Institute
Hudson Institute’ s research programs deliver in five areas of medical need – inflammation, cancer, reproductive health, newborn health, and hormones and health. More
Hudson News
Get the inside view on discoveries and patient stories
“Thank you Hudson Institute researchers. Your work brings such hope to all women with ovarian cancer knowing that potentially women in the future won't have to go through what we have!”